ClinicalTrials.gg
CompletedNCT01751308Updated Aug 12, 2016Results posted

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

A Phase 1/2 interventional study of Cabazitaxel (XRP6258) in Malignant Solid Tumor - Malignant Nervous System Neoplasm, sponsored by Sanofi. Completed at 13 sites in 2 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-08-12.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Nervous System Neoplasms with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Nervous System Neoplasms · United States.

Enrollment
5th of 12
39 · median 32
Started
2013
the only one that year
Phase 1/2
4 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Sanofi

Among the 14 studies in Nervous System Neoplasms with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 1/2, and was the 9th registered.

Nervous System Neoplasms

19 studies on the registry are indexed under Nervous System Neoplasms; 8 are open to participants now.

Browse Nervous System Neoplasms studies →

Open to participants now

6 of the 14 studies in Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Nervous System Neoplasms studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Nervous System Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Primary Objectives:

Phase 1 Part:

To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric participants with recurrent or refractory solid tumors including tumors of the central nervous system.

Phase 2 Part:

To determine the objective response rate (complete and partial response) and the duration of response to cabazitaxel as a single agent in participants with recurrent or refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG).

Secondary Objectives:

Phase 1 Part:

To characterize the safety and tolerability of cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.

To characterize the pharmacokinetic (PK) profile of cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.

To evaluate preliminary anti-tumor activity that may be associated with cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.

Phase 2 Part:

To characterize the safety and tolerability of cabazitaxel in participants with recurrent or refractory HGG or DIPG.

To estimate progression free survival in participants with recurrent or refractory HGG or DIPG.

To estimate overall survival in participants with recurrent or refractory HGG or DIPG.

To characterize the plasma PK profile of cabazitaxel in participants with recurrent or refractory HGG or DIPG.

Read the detailed description

The study duration will include a period for inclusion of up to 3 weeks and a 3-week treatment cycle(s). The participants may continue treatment until disease progression, unacceptable toxicity or willingness to stop followed by a minimum of 30-day follow-up.

03

Conditions studied

  • Malignant Solid Tumor - Malignant Nervous System Neoplasm
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1 Part (dose escalation): Participants with a confirmed solid tumor including tumors of the central nervous system that was recurrent or and for which no further effective standard treatment was available. All participants must had . Participants with diffuse pontine glioma were eligible without a after evidence of progressive disease post radiation therapy.

Phase 2 Part (safety and activity): Participants with recurrent or refractory high grade glioma or diffuse intrinsic pontine glioma for whom no further effective therapy was available. All participants must had measurable disease. Participants with diffuse pontine glioma were eligible without a biopsy after evidence of progressive disease post radiation therapy. Participants with a grade III or grade IV glioma must had pathologic confirmation either at the time of initial diagnosis or at the time of recurrence.

Participants aged ≥2 years and ≤18 years

Participants met the body surface area (BSA) requirements to be eligible:

  1. Minimal BSA requirements for a particular dose level;
  2. During the Phase 1 part participants must had a BSA \<2.1 m² at the time of enrollment
  3. During the Phase 2 part participants with a BSA ≥2.1 m² were eligible, however the actual dose of cabazitaxel for these participants were adjusted to a maximum dose calculated with (capped at) the BSA of 2.1 m²

Performance status by:

  1. Lansky score ≥60 (participants ≤10 years of age)
  2. score ≥60% (participants >10 years of age) Participants who were unable to walk because of paralysis, but who were mobile in a wheelchair, were considered ambulatory for the purpose of assessing the performance score.

Participants must had adequate liver, renal and marrow function as defined below:

  1. Total ≤1.0 x the (ULN) for age
  2. (SGOT) and ALT (SGPT) ≤2.5 x ULN
  3. Serum creatinine ≤1.5 x ULN for age or ≥60 mL/min/1.73 m²
  4. ≥1.0x10\^9 /L
  5. ≥75x10\^9/L (transfusion independent)
  6. ≥8.0 g/dL (could be transfused)

Female participants of must had a negative pregnancy test ≤7 days before starting cabazitaxel treatment.

Male and female participants of must agreed to use adequate prior to study entry, for the duration of study participation and for 6 months following the last dose of cabazitaxel.

Written /assent prior to any study-specific procedures. Consent must be obtained from the participant and/or parent(s) or legal guardian(s) and the signature of at least one parent or guardian was required. Investigators also obtained assent of participants according to local, regional or national guidelines.

Participants must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering the study.

Exclusion criteria

Exclusion criteria:

Prior treatment within the following timeframes:

  1. Systemic anti-cancer treatment within 3 weeks (6 weeks for nitrosourea, mitomycin and monoclonal antibodies including bevacizumab)
  2. Surgery or smaller field radiation therapy within 4 weeks
  3. Treatment with an agent within 4 weeks or within 5 half-lives of the agent, whichever was longer Craniospinal or other large field radiation therapy (defined as >25% of bone marrow irradiated) within 6 months prior to the first dose.

Prior systemic radioisotope therapy (this did not include diagnostic imaging or radioimmunoconjugates lacking myelosuppressive properties) or total body irradiation.

Prior bone marrow or stem cell transplant

Participants with any illness that, in the investigator's opinion, could not be adequately controlled with appropriate therapy, would compromise a participant's ability to tolerate cabazitaxel or result in inability to assess toxicity. This included, but was not limited to uncontrolled intercurrent illness including ongoing or active infection, cardiac disease, renal impairment, planned surgery or psychiatric illness/social situations that would limit compliance with study requirements.

Known (HIV) infection or acquired immunodeficiency-syndrome (AIDS)-related disease Known history of or known active infection. Pregnant or breast feeding women Treatment with strong inhibitors or strong inducers of or enzyme inducing anti-epileptic drugs (EIAED) within 14 days prior to first dose of cabazitaxel and for the duration of study. Non-EIAEDs were permitted.

Known history of to taxanes or polysorbate 80 or G-CSF. Participation in another interventional clinical trial and/or concurrent treatment with any investigational drug.

Participants not able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Phase 1: Cabazitaxel 20 mg/m^2

    Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Phase 1: Cabazitaxel 25 mg/m^2

    Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Phase 1: Cabazitaxel 30 mg/m^2

    Cabazitaxel 30 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Phase 1: Cabazitaxel 35 mg/m^2

    Cabazitaxel 35 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).

    Drug: Cabazitaxel (XRP6258)

  • Experimental
    Phase 2: Cabazitaxel 30 mg/m^2

    Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m\^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).

    Drug: Cabazitaxel (XRP6258)

Interventions

  • Pharmaceutical form: Injection Route of administration: Intravenous

    Also known as: Jevtana

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose of Cabazitaxel

    MTD was highest dose level of cabazitaxel at which no more than 1 of 6 evaluable participants experienced dose limiting toxicities (DLT). DLT defined as an AE or abnormal laboratory values related to study treatment: hematologic DLTs: any Grade(G)4 hematologic toxicity except neutropenia G4 lasting≤7 days,G3 or 4 febrile neutropenia except G3 or 4 febrile neutropenia in absence of granulocyte-colony stimulating factor prophylaxis, G4 thrombocytopenia; non-hematologic DLTs:any G≥3 non-hematologic toxicity except G3 nausea or G3 or4 vomiting, G3 or4 diarrhea,G3 or4 dehydration,G3 fatigue lasting≤7 days, inadequately treated hypersensitivity reactions, elevated transaminases\<10\* upper limit of normal of ≤7 days, re-treatment delay of\>2 weeks due to delayed recovery from toxicity related to study treatment to baseline G or≤ G1(except for alopecia) and platelet transfusion during Cycle1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

    Time frame: Cycle 1 (21 days)

  2. Phase 2: Percentage of Participants With Objective Response (OR)

    OR in participants was defined as the participants with a Complete Response (CR) or Partial Response (PR) after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks. CR and PR were based on modified response assessment in neuro-oncology (RANO) criteria for participants with CNS tumors. CR was defined as disappearance of all target lesions. PR was defined as ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to the baseline measurement.

    Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)

  3. Phase 2: Duration of Response (DOR)

    DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. If progression or death was not observed, participant was censored at the date of participant's last progression-free tumor assessment prior to study cut-off date. PD as per RANO criteria was defined as ≥ 25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc.) plus any increase in tumor cross-sectional area (or tumor volume).

    Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)

Secondary outcomes

  1. Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. Treatment emergent adverse events (TEAEs) were defined as AEs that developed or worsened in grade or became serious during the on-treatment period which was defined as the period from the time of first dose of cabazitaxel until 30 days following the last administration of cabazitaxel.

    Time frame: Baseline up to DP or death due to any cause (maximum duration: 112.1 weeks for Phase 1 and 12.1 weeks for Phase 2)

  2. Phase 1: Number of Participants With Objective Response

    OR in participants was defined as the participants with a CR or PR after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1 and RANO criteria for CNS tumors. For solid tumors, as per RECIST 1.1, CR defined as disappearance of all target and non-target lesions (any pathological lymph nodes, must had reduction in short axis to \<10 mm); PR defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For CNS tumors, as per RANO criteria, CR defined as disappearance of all target and non-target lesions; PR defined as a ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to baseline measurement.

    Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 112.1 weeks)

  3. Phase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve

    Blood samples for PK parameters were collected at 5 minutes before end of infusion (EOI), 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

    Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI

  4. Phase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL)

    Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

    Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI

  5. Phase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss)

    Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

    Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI

  6. Phase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax)

    Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

    Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI

  7. Phase 2: Progression Free Survival (PFS)

    The PFS was defined as the time (in months) from the date of first dose administration until the date of first documented PD or death (from any cause), whichever came first. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. PD as per RANO criteria was defined as ≥25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) plus any increase in tumor cross-sectional area (or tumor volume). The analysis was performed by Kaplan-Meier method.

    Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)

  8. Phase 2: Overall Survival (OS)

    OS was defined as the time (in months) from the date of first dose administration until the date of death (from any cause). If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive and the study cut-off date. The analysis was performed by Kaplan-Meier method.

    Time frame: Baseline up to death or study cut-off (maximum duration: 12.1 weeks)

07

Results

Posted Aug 12, 2016

Participant flow

Participants were enrolled at 12 centers between February 2013 and March 2015.

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2
Started63770
Completed63770
Not completed00000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2
Started000016
Completed000016
Not completed00000

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose of Cabazitaxel

MTD was highest dose level of cabazitaxel at which no more than 1 of 6 evaluable participants experienced dose limiting toxicities (DLT). DLT defined as an AE or abnormal laboratory values related to study treatment: hematologic DLTs: any Grade(G)4 hematologic toxicity except neutropenia G4 lasting≤7 days,G3 or 4 febrile neutropenia except G3 or 4 febrile neutropenia in absence of granulocyte-colony stimulating factor prophylaxis, G4 thrombocytopenia; non-hematologic DLTs:any G≥3 non-hematologic toxicity except G3 nausea or G3 or4 vomiting, G3 or4 diarrhea,G3 or4 dehydration,G3 fatigue lasting≤7 days, inadequately treated hypersensitivity reactions, elevated transaminases\<10\* upper limit of normal of ≤7 days, re-treatment delay of\>2 weeks due to delayed recovery from toxicity related to study treatment to baseline G or≤ G1(except for alopecia) and platelet transfusion during Cycle1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · mg/m^2
Phase 1: Maximum Tolerated Dose of Cabazitaxel
mg/m^2Phase 1: Overall Population
Phase 1: Maximum Tolerated Dose of Cabazitaxel30
PrimaryPhase 2: Percentage of Participants With Objective Response (OR)

OR in participants was defined as the participants with a Complete Response (CR) or Partial Response (PR) after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks. CR and PR were based on modified response assessment in neuro-oncology (RANO) criteria for participants with CNS tumors. CR was defined as disappearance of all target lesions. PR was defined as ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to the baseline measurement.

Time frame:
Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Objective Response (OR)
percentage of participantsPhase 2: Cabazitaxel 30 mg/m^2
CR0
PR0
PrimaryPhase 2: Duration of Response (DOR)

DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. If progression or death was not observed, participant was censored at the date of participant's last progression-free tumor assessment prior to study cut-off date. PD as per RANO criteria was defined as ≥ 25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc.) plus any increase in tumor cross-sectional area (or tumor volume).

Time frame:
Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)

No measurements were reported for this outcome.

SecondaryPhase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. Treatment emergent adverse events (TEAEs) were defined as AEs that developed or worsened in grade or became serious during the on-treatment period which was defined as the period from the time of first dose of cabazitaxel until 30 days following the last administration of cabazitaxel.

Time frame:
Baseline up to DP or death due to any cause (maximum duration: 112.1 weeks for Phase 1 and 12.1 weeks for Phase 2)
Reported as:
Number · participants
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)637716
SecondaryPhase 1: Number of Participants With Objective Response

OR in participants was defined as the participants with a CR or PR after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1 and RANO criteria for CNS tumors. For solid tumors, as per RECIST 1.1, CR defined as disappearance of all target and non-target lesions (any pathological lymph nodes, must had reduction in short axis to \<10 mm); PR defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For CNS tumors, as per RANO criteria, CR defined as disappearance of all target and non-target lesions; PR defined as a ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to baseline measurement.

Time frame:
Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 112.1 weeks)
Reported as:
Number · participants
Phase 1: Number of Participants With Objective Response
participantsPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2
Phase 1: Number of Participants With Objective Response1000
SecondaryPhase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve

Blood samples for PK parameters were collected at 5 minutes before end of infusion (EOI), 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

Time frame:
Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Reported as:
Mean · ng.h/mL
Phase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve
ng.h/mLPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1 and 2: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2
Phase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve669.5 ± 430.6879.0 ± 414.7876.7 ± 359.91002.5 ± 277.9
SecondaryPhase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL)

Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

Time frame:
Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Reported as:
Mean · L/h/m^2
Phase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL)
L/h/m^2Phase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1 and 2: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2
Phase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL)36.05 ± 12.9132.76 ± 12.7238.70 ± 12.9836.61 ± 9.98
SecondaryPhase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss)

Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

Time frame:
Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Reported as:
Mean · L/m^2
Phase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss)
L/m^2Phase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1 and 2: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2
Phase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss)3391.72 ± 686.793301.96 ± 351.553371.30 ± 975.981488.75 ± 1179.11
SecondaryPhase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax)

Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.

Time frame:
Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Reported as:
Mean · ng/mL
Phase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax)
ng/mLPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1 and 2: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2
Phase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax)204.864 ± 189.864283.657 ± 242.970256.734 ± 127.931233.290 ± 0.127
SecondaryPhase 2: Progression Free Survival (PFS)

The PFS was defined as the time (in months) from the date of first dose administration until the date of first documented PD or death (from any cause), whichever came first. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. PD as per RANO criteria was defined as ≥25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) plus any increase in tumor cross-sectional area (or tumor volume). The analysis was performed by Kaplan-Meier method.

Time frame:
Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS)
monthsPhase 2: Cabazitaxel 30 mg/m^2
Phase 2: Progression Free Survival (PFS)1.3 (0.6 to 2.1)
SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time (in months) from the date of first dose administration until the date of death (from any cause). If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive and the study cut-off date. The analysis was performed by Kaplan-Meier method.

Time frame:
Baseline up to death or study cut-off (maximum duration: 12.1 weeks)
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2: Cabazitaxel 30 mg/m^2
Phase 2: Overall Survival (OS)2.7 (1.7 to 4.5)

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (112.1 weeks for Phase 1 and 12.1 weeks for Phase 2) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Cabazitaxel 20 mg/m^2—4/6 (66.7%)6/6 (100%)
Phase 1: Cabazitaxel 25 mg/m^2—1/3 (33.3%)3/3 (100%)
Phase 1: Cabazitaxel 30 mg/m^2—5/7 (71.4%)7/7 (100%)
Phase 1: Cabazitaxel 35 mg/m^2—3/7 (42.9%)7/7 (100%)
Phase 2: Cabazitaxel 30 mg/m^2—12/16 (75%)15/16 (93.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders1/61/31/72/73/16
Varicella zoster virus infectionInfections and infestations0/61/30/70/70/16
Platelet count decreasedInvestigations0/61/30/70/70/16
Disease progressionGeneral disorders1/60/30/70/73/16
Anaphylactic reactionImmune system disorders0/60/30/70/73/16
GastroenteritisInfections and infestations1/60/30/70/70/16
Intracranial tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/31/70/71/16
Cystitis noninfectiveRenal and urinary disorders1/60/30/70/70/16
NeutropeniaBlood and lymphatic system disorders0/60/31/70/70/16
DiarrhoeaGastrointestinal disorders0/60/30/71/72/16
Most frequent other events
Showing 10 of 124
Most frequent other events
EventPhase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2
VomitingGastrointestinal disorders0/62/33/72/74/16
HeadacheNervous system disorders4/61/31/72/74/16
CoughRespiratory, thoracic and mediastinal disorders0/62/33/71/70/16
DiarrhoeaGastrointestinal disorders2/61/34/71/75/16
Abdominal painGastrointestinal disorders0/61/31/73/72/16
NauseaGastrointestinal disorders2/61/33/72/75/16
FatigueGeneral disorders2/61/32/73/73/16
DysphagiaGastrointestinal disorders0/60/30/70/76/16
AnaemiaBlood and lymphatic system disorders1/61/32/71/71/16
Sinus tachycardiaCardiac disorders1/61/31/71/70/16

Baseline characteristics

All treated (AT)/safety population was defined as all registered participants who actually received at least 1 dose or part of a dose of the investigational medicinal product (IMP).

Age, Customized
Age, Customized(participants)Phase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2Total
2-4 years002024
5-6 years210148
7-11 years1135414
12-18 years3121613
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Cabazitaxel 20 mg/m^2Phase 1: Cabazitaxel 25 mg/m^2Phase 1: Cabazitaxel 30 mg/m^2Phase 1: Cabazitaxel 35 mg/m^2Phase 2: Cabazitaxel 30 mg/m^2Total
Female5012816
Male1365823
08

Study locations

13 sites
  • Investigational Site Number 840009
    Phoenix, Arizona 85006, United States
  • Investigational Site Number 840013
    Los Angeles, California 90027, United States
  • Investigational Site Number 840014
    Palo Alto, California, United States
  • Investigational Site Number 840007
    Aurora, Colorado 80045, United States
  • Investigational Site Number 840011
    Washington, District of Columbia 20010, United States
  • Investigational Site Number 840005
    Orlando, Florida 32806, United States
  • Investigational Site Number 840012
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840010
    Baltimore, Maryland 21287, United States
  • Investigational Site Number 840002
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840003
    New York, New York 10021, United States
  • Investigational Site Number 840006
    Houston, Texas 77030, United States
  • Investigational Site Number 840008
    Seattle, Washington 98105, United States
  • Investigational Site Number 124001
    Toronto, M5G 1X8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Jul 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 17, 2012
Start
Feb 2013
Primary completionActual
Jul 2015
CompletionActual
Feb 2016
Results first posted
Aug 12, 2016
Last update
Aug 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01751308
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Feb 2013
Primary completion
Jul 2015
Completion
Feb 2016
Results posted
Aug 12, 2016
Last update
Aug 12, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion